Research Article
HIV Suppression among Patients on Treatment in Vietnam: A Review of HIV Viral Load Testing in a Public Urban Clinic in Ho Chi Minh City
Table 1
Baseline characteristics of patients on ART >1 yr who received VL testing, .
| | Characteristic | |
| | Male (%) | 193 (85) | | Female (%) | 35 (15) | | Age at study, median (interquartile range), years | 30 (27–34) | | Age at ART initiation, median (interquartile range) years | 27 (24–31) | | IDU (%) | 175 (77) | | Prior ART exposure (%) | 30 (13) | | Duration of ARV at time of viral load testing, mean (95% CI), months | 26 (25–27) | | Adherence: “Good” (%) | 169 (74) | | Adherence: “Poor” (%) | 59 (26) | | First-line regimen | | | AZT/3TC/EFV | 4 (2) | | AZT/3TC/NVP | 14 (6) | | D4T/3TC/EFV | 61 (27) | | D4T/3TC/NVP | 149 (65) | | CD4 cell count, median (interquartile range) cells/μL | | | at registration to An Hoa OPC | 57 (18–146) | | at viral load testing | 240 (144–366) | | Documented immunologic failure (%) | 39 (17) | | Documented clinical failure (%) | 14 (6) | | Switch to 2nd line* (%) | 13 (6) | | VL testing | | | according to targeted approach (%) | 29 (13) | | according to routine approach (%) | 199 (87) |
|
|
IDU: injection drug use, VL: viral load.
ART: antiretroviral therapy.
AZT: zidovudine, D4T: stavudine, EFV: efavirenz.
NVP: nevirapine, 3TC: lamivudine.
*Second-line regimen: tenofovir (TDF)/lamivudine (3TC)/lopinavir (LPV).
|
